ASO Author Reflections: Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Pancreatic Cancer Based on Tumor Location: Should We Dissect Non-Peripancreatic Lymph Nodes for all Left-Sided Pancreatic Cancer Patients?

Hiroyuki Ishida^{1

2}, Toshiro Ogura^{3

4}, Amane Takahashi¹

Affiliations

¹ Department of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
² Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
³ Department of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan. mexicouxmal@gmail.com.
⁴ Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan. mexicouxmal@gmail.com.

Comment

Hiroyuki Ishida et al. Ann Surg Oncol. 2022 Apr.

. 2022 Apr;29(4):2425-2426.

doi: 10.1245/s10434-021-11115-6. Epub 2022 Jan 7.

Hiroyuki Ishida^{1

2}, Toshiro Ogura^{3

4}, Amane Takahashi¹

¹ Department of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan.
² Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan.
³ Department of Gastroenterological Surgery, Saitama Cancer Center, Saitama, Japan. mexicouxmal@gmail.com.
⁴ Department of Hepatobiliary and Pancreatic Surgery, Tokyo Medical and Dental University, Tokyo, Japan. mexicouxmal@gmail.com.

No abstract available

Comment on

Optimal Region of Lymph Node Dissection in Distal Pancreatectomy for Left-Sided Pancreatic Cancer Based on Tumor Location.
Ishida H, Ogura T, Takahashi A, Miyamoto R, Matsudaira S, Amikura K, Tanabe M, Kawashima Y. Ishida H, et al. Ann Surg Oncol. 2022 Apr;29(4):2414-2424. doi: 10.1245/s10434-021-11108-5. Epub 2021 Nov 26. Ann Surg Oncol. 2022. PMID: 34837132

1. Tanaka K, Nakamura T, Asano T, et al. Pancreatic body and tail cancer and favorable metastatic lymph node behavior on the left edge of the aorta. Pancreatology. 2020;20(7):1451–7. https://doi.org/10.1016/j.pan.2020.08.014 . - DOI - PubMed
1. Imamura T, Yamamoto Y, Sugiura T, et al. Reconsidering the optimal regional lymph node station according to tumor location for pancreatic cancer. Ann Surg Oncol. 2021;28(3):1602–11. https://doi.org/10.1245/s10434-020-09066-5 . - DOI - PubMed
1. Ishida H, Ogura T, Takahashi A, et al. Optimal region of lymph node dissection in distal pancreatectomy for left-sided pancreatic cancer based on tumor location. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-11108-5 . - DOI - PubMed
1. Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473–81. https://doi.org/10.1001/jama.2013.279201 . - DOI - PubMed
1. Uesaka K, Boku N, Fukutomi A, et al. Adjuvant chemotherapy of S-1 versus gemcitabine for resected pancreatic cancer: a phase 3, open-label, randomised, non-inferiority trial (JASPAC 01). Lancet. 2016;388(10041):248–57. https://doi.org/10.1016/S0140-6736(16)30583-9 . - DOI - PubMed